SanaGen was incorporated in 2019 and is headquartered at the New West Health & Innovation District in Amsterdam, The Netherlands. SanaGen focuses on gene therapy approaches for rare genetic disorders that can provide a life-long cure for many diseases. SanaGen is a pioneering company that focuses on transparency of costs and exploring creative ways to reduce development costs, as well as on innovative sales and contracting models for getting products to patients, and production built to serve both developed and developing countries. SanaGen develops these new gene therapies in collaboration with the research group of Prof. dr. Jan Voorberg of Sanquin Research and Prof. dr. Joost Verhaagen of The Netherlands Institute of Neuroscience.
Our current portfolio includes the development of gene therapy for patients with factor VII and X deficiency. These rare bleeding disorders affect one in 300,000-500,000 people and current treatment for these disorders are suboptimal. Building on our extensive knowledge in the field of hemostasis as well as gene therapy development we are also focusing on gene therapy approaches for other bleeding disorders. Over 3 decades of gene therapy research and experimentation have led to a rapidly innovating industry which is on the brink of treating many different genetic disorders. The principal founders of SanaGen are experts in both basic and clinical studies on bleeding disorders and also include experts with detailed knowledge on global markets for these disorders.
SanaGen is founded and headed by David Mosmuller, MD PhD. He is a medical doctor with a business mindset with extensive experience in clinical research, life sciences, medicine, regulatory affairs, and pharmacovigilance.